The JOBS ActOn April 5th, the Jumpstart Our Business Startups Act (the JOBS Act), landmark legislation that makes significant changes to both the Securities Act of '33 and the Securities Exchange Act of '34. The bill's objective is to make it easier for companies to raise capital by easing the regulatory burdens, restrictions and costs presently associated with capital formation. The JOBS Act will have significant ramifications for both public and private emerging growth companies. Find out what it means to you by downloading our summary here.
Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Burrill & Company's Institutional Equities business provides institutional clients with seasoned equity advice and capital markets expertise focused on all aspects of the life sciences and biogreentech. Our institutional equities division compliments our merchant banking, private equity, and venture groups by raising capital through public offerings and private placements.
Buy-side relationships; 10b-18 corporate relationships; deep sector expertise
Relationship managers with knowledge of life sciences and biogreentech
Providing clients with direct exposure to industries, companies, and management.
A highly regarded management team with deep expertise across the life sciences offering industry-leading advice.
At the market programs allow companies to tap into the existing secondary market for their shares on an as-and-when-needed basis.